Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography (RESIST)

Matthieu Pelletier-Galarneau, MD MSc

Status: Completed

Conditions: Renal Microcirculation With Rubidium Positron Emission Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT06332456

ICM 2023-3169

Details and patient eligibility

About

The aim of this study is to demonstrate that positron emission tomography imaging with Rubidium-82 (radioactive tracer) can non-invasively detect and quantify changes in renal blood flow (renal perfusion) and renal vascular resistance in both healthy subjects and patients with renal insufficiency. Ultimately, the results of this study will contribute to a better understanding of the role of positron emission imaging in the evaluation of patients with renal diseases.

Full description

2. Hypothesis

3. We hypothesize that RBF assessed with rubidium PET is on average lower in patients with CKD. To test our hypothesis, RBF of patients with CKD and coronary artery disease (CAD) risk factors, a population characterized by renal microvascular rarefaction, will be compared to RBF of healthy controls.

4. We hypothesize that RVR assessed with rubidium PET correlates with echographic measurements of renal resistance index (RI), the current non-invasive method of choice.

5. We hypothesize that RBF quantification with rubidium PET is technically reproducible, meaning that the variation on the measurements of RBF purely attributable to technical factors (camera, positioning, tracer injection, etc.) is relatively small. To test this hypothesis, two PET scans will be acquired within a short time period.

6. Objectives and Endpoints 3.1. Primary Objective

1. To compare RBF of patients with CKD and CAD risk factors to healthy controls 3.2. Secondary Objectives

1. To compare RVR of patients with CKD and CAD risk factors to healthy controls
2. To evaluate the correlation between RVR measured with PET to renal RI as measured with echography
3. To evaluate the repeatability and reproducibility of in vivo measurements of RBF and RVR

Enrollment: 30 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Control Group

1. Age ≥ 18 years and < 80 years
2. Signed informed consent
3. No medical history of renal disease

CKD Group

1. Age ≥ 18 years and < 80 years
2. Signed informed consent
3. GFR between 30 and 45 mL/min/1.73m2 measured within the last 3 months
4. At least two cardiovascular disease risk factors such as hypertension, smoking, diabetes, obesity, and dyslipidemia

Exclusion criteria

Control Group

1. Hypertension
2. Diabetes
3. Dyslipidemia
4. Active smoking within the last 12 month
5. Left ventricular ejection fraction <45%
6. BMI >45 kg/m2
7. Severe aortic stenosis

CKD Group

1. Left ventricular ejection fraction <45%
2. BMI >45 kg/m2
3. Severe aortic stenosis
4. Changes in medical therapy within the last 4 weeks
5. Documented renal artery stenosis
6. Known structural cause of CKD including polycystic kidney disease, obstruction, or other post-renal causes
7. Pregnancy or breastfeeding
8. Renal failure requiring dialysis within the last 90 days

Trial design

30 participants in 2 patient groups

Control

Description:

15 healthy volunteers

CKD

Description:

15 patients with CKD and CAD risk factors with GFR between 30 and 45 mL/min/1.73m2